1 S. Saghafinia, M. Mina, N. Riggi, D. Hanahan, G. CirielloPan-cancer landscape of aberrant DNA methylation across human tumors Cell Rep, 25 (4) (2018), pp. 1066-1080 e8

2 F. Köhler, M. Rodríguez-ParedesDNA methylation in epidermal differentiation, aging, and cancer J Invest Dermatol, 140 (1) (2020), pp. 38-47

3 J.E. Audia, R.M. CampbellHistone modifications and cancer Cold Spring Harbor Perspect Biol, 8 (4) (2016), p. a019521

4 A.M. Valencia, C. KadochChromatin regulatory mechanisms and therapeutic opportunities in cancer Nat Cell Biol, 21 (2) (2019), pp. 152-161

5 S. Wang, C. Sun, J. Li, et al.Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers Cancer Lett, 408 (2017), pp. 112-120

6 H. Weng, H. Huang, H. Wu, et al.METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m 6 A modification Cell Stem Cell, 22 (2) (2018), pp. 191-205 e9

7 T. Wang, S. Kong, M. Tao, S. JuThe potential role of RNA N6-methyladenosine in Cancer progression Mol Cancer, 19 (1) (2020), p. 88

8 C. Gu, X. Shi, C. Dai, et al.RNA m 6 A modification in cancers: molecular mechanisms and potential clinical applications Innovation, 1 (3) (2020), p. 100066

9 H. Yin, X. Zhang, P. Yang, et al.RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming Nat Commun, 12 (1) (2021), p. 1394

10 GeulaS, S. Moshitch-Moshkovitz, D. Dominissini, et al.Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation Science, 347 (6225) (2015), pp. 1002-1006

11 X. Wang, J. Feng, Y. Xue, et al.Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex Nature, 534 (7608) (2016), pp. 575-578

12 X.L. Ping, B.F. Sun, L. Wang, et al.Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase Cell Res, 24 (2) (2014), pp. 177-189

13 Y. Yue, J. Liu, X. Cui, et al.VIRMA mediates preferential m 6 A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation Cell Discov, 4 (2018), p. 10

14 K. Horiuchi, T. Kawamura, H. Iwanari, et al.Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle J Biol Chem, 288 (46) (2013), pp. 33292-33302

15 J. Wen, R. Lv, H. Ma, et al.Zc3h13 regulates nuclear RNA m 6 A methylation and mouse embryonic stem cell self-renewal Mol Cell, 69 (6) (2018), pp. 1028-1038 e6

16 A.S. Warda, J. Kretschmer, P. Hackert, et al.Human METTL16 is a N6-methyladenosine (m 6 A) methyltransferase that targets pre-mRNAs and various non-coding RNAs EMBO Rep, 18 (11) (2017), pp. 2004-2014

17 K.E. Pendleton, B. Chen, K. Liu, et al.The U6 snRNA m 6 A methyltransferase METTL16 regulates SAM synthetase intron retention Cell, 169 (5) (2017), pp. 824-835 e14

18 G. Jia, Y. Fu, X. Zhao, et al.N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO Nat Chem Biol, 7 (12) (2011), pp. 885-887

19 G. Zheng, J.A. Dahl, Y. Niu, et al.ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility Mol Cell, 49 (1) (2013), pp. 18-29

20 X. Wang, B.S. Zhao, I.A. Roundtree, et al.N(6)-methyladenosine modulates messenger RNA translation efficiency Cell, 161 (6) (2015), pp. 1388-1399

21 O.H. Park, H. Ha, Y. Lee, et al.Endoribonucleolytic cleavage of m 6 A-containing RNAs by RNase P/MRP complex Mol Cell, 74 (3) (2019), pp. 494-507 e8

22 H. Shi, X. Wang, Z. Lu, et al.YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA Cell Res, 27 (3) (2017), pp. 315-328

23 W. Xiao, S. Adhikari, U. Dahal, et al.Nuclear m(6)A reader YTHDC1 regulates mRNA splicing Mol Cell, 61 (4) (2016), pp. 507-519

24 I.A. Roundtree, G.Z. Luo, Z. Zhang, et al.YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs Elife, 6 (2017), p. e31311

25 P.J. Hsu, Y. Zhu, H. Ma, et al.Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis Cell Res, 27 (9) (2017), pp. 1115-1127

26 Y. Mao, L. Dong, X.M. Liu, et al.m 6 A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2 Nat Commun, 10 (1) (2019), p. 5332

27 B. Wu, S. Su, D.P. Patil, et al.Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1 Nat Commun, 9 (1) (2018), p. 420

28 Y. Wang, Y. Li, J.I. Toth, M.D. Petroski, Z. Zhang, J.C. ZhaoN6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells Nat Cell Biol, 16 (2) (2014), pp. 191-198

29 H.B. Li, J. Tong, S. Zhu, et al.m 6 A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways Nature, 548 (7667) (2017), pp. 338-342

30 Y. Chen, J. Wang, D. Xu, et al.m 6 A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells Autophagy, 17 (2) (2021), pp. 457-475

31 C. Church, L. Moir, F. McMurray, et al.Overexpression of Fto leads to increased food intake and results in obesity Nat Genet, 42 (12) (2010), pp. 1086-1092

32 S.D. Kasowitz, J. Ma, S.J. Anderson, et al.Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development PLoS Genet, 14 (5) (2018), p. e1007412

33 L. Li, L. Zang, F. Zhang, et al.Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis Hum Mol Genet, 26 (13) (2017), pp. 2398-2411

34 K.J. Yoon, F.R. Ringeling, C. Vissers, et al.Temporal control of mammalian cortical neurogenesis by m 6 A methylation Cell, 171 (4) (2017), pp. 877-889 e17

35 Y. Wang, Y. Li, M. Yue, et al.N 6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications Nat Neurosci, 21 (2) (2018), pp. 195-206

36 L.P. Vu, B.F. Pickering, Y. Cheng, et al.The N 6-methyladenosine (m 6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells Nat Med, 23 (11) (2017), pp. 1369-1376

37 J. Lv, Y. Zhang, S. Gao, et al.Endothelial-specific m 6 A modulates mouse hematopoietic stem and progenitor cell development via Notch signaling Cell Res, 28 (2) (2018), pp. 249-252

38 J. Tong, G. Cao, T. Zhang, et al.m 6 A mRNA methylation sustains Treg suppressive functions Cell Res, 28 (2) (2018), pp. 253-256

39 J. Liu, X. Zhang, K. Chen, et al.CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis Immunity, 50 (3) (2019), pp. 600-615 e15

40 Z. Zheng, L. Zhang, X.L. Cui, et al.Control of early B cell development by the RNA N6-methyladenosine methylation Cell Rep, 31 (13) (2020), p. 107819

41 H. Bansal, Q. Yihua, S.P. Iyer, et al.WTAP is a novel oncogenic protein in acute myeloid leukemia Leukemia, 28 (5) (2014), pp. 1171-1174

42 C. Zhang, D. Samanta, H. Lu, et al.Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m ⁶A-demethylation of NANOG mRNA Proc Natl Acad Sci USA, 113 (14) (2016), pp. E2047-E2056

43 M. Cheng, L. Sheng, Q. Gao, et al.The m 6 A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network Oncogene, 38 (19) (2019), pp. 3667-3680

44 S. Zhou, Z.L. Bai, D. Xia, et al.FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation Mol Carcinog, 57 (5) (2018), pp. 590-597

45 F. Li, Y. Yi, Y. Miao, et al.N6-methyladenosine modulates nonsense-mediated mRNA decay in human glioblastoma Cancer Res, 79 (22) (2019), pp. 5785-5798

46 R. Zhou, Y. Gao, D. Lv, C. Wang, D. Wang, Q. LiMETTL3 mediated m 6 A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ΔNp63 Biochem Biophys Res Commun, 515 (2) (2019), pp. 310-317

47 E. Orouji, W.K. Peitsch, A. Orouji, R. Houben, J. UtikalOncogenic role of an epigenetic reader of m 6 A RNA modification: YTHDF1 in merkel cell carcinoma Cancers, 12 (1) (2020), p. 202

48 Y. Lin, S. Wang, S. Liu, S. Lv, H. Wang, F. LiIdentification and verification of molecular subtypes with enhanced immune infiltration based on m6A regulators in cutaneous melanoma BioMed Res Int, 2021 (2021), p. 2769689

49 E. Soura, E. Gagari, A. StratigosAdvanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr Opin Oncol, 31 (5) (2019), pp. 461-468

50 S.K.T. Que, F.O. Zwald, C.D. SchmultsCutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging J Am Acad Dermatol, 78 (2) (2018), pp. 237-247

51 K.D. Brantsch, C. Meisner, B. Schönfisch, et al.Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study Lancet Oncol, 9 (8) (2008), pp. 713-720

52 N.D. Brougham, E.R. Dennett, R. Cameron, S.T. TanThe incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors J Surg Oncol, 106 (7) (2012), pp. 811-815

53 W. Zhao, Y. Cui, L. Liu, et al.METTL3 facilitates oral squamous cell carcinoma tumorigenesis by enhancing c-myc stability via YTHDF1-mediated m 6 A modification Mol Ther Nucleic Acids, 20 (2020), pp. 1-12

54 L. Liu, Y. Wu, Q. Li, et al.METTL3 promotes tumorigenesis and metastasis through BMI1 m 6 A methylation in oral squamous cell carcinoma Mol Ther, 28 (10) (2020), pp. 2177-2190

55 Z. Yang, S. Yang, Y.H. Cui, et al.METTL14 facilitates global genome repair and suppresses skin tumorigenesis Proc Natl Acad Sci USA, 118 (35) (2021) e2025948118

56 Y. Ban, P. Tan, J. Cai, et al.LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma Mol Oncol, 14 (6) (2020), pp. 1282-1296

57 P. Wu, X. Fang, Y. Liu, et al.N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway Cell Death Dis, 12 (4) (2021), p. 298

58 T.M. Frayling, N.J. Timpson, M.N. Weedon, et al.A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity Science, 316 (5826) (2007), pp. 889-894

59 Y. Cao, Y. Zhuang, J. Chen, et al.Dynamic effects of Fto in regulating the proliferation and differentiation of adult neural stem cells of mice Hum Mol Genet, 29 (5) (2020), pp. 727-735

60 Z. Li, H. Weng, R. Su, et al.FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase Cancer Cell, 31 (1) (2017), pp. 127-141

61 R. Su, L. Dong, C. Li, et al.R-2HG exhibits anti-tumor activity by targeting FTO/m 6 A/MYC/CEBPA signaling Cell, 172 (1–2) (2018), pp. 90-105 e23

62 Y.H. Cui, S. Yang, J. Wei, et al.Autophagy of the m 6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis Nat Commun, 12 (1) (2021), p. 2183

63 V.D. Martinez, E.A. Vucic, D.D. Becker-Santos, L. Gil, W.L. LamArsenic exposure and the induction of human cancers J Toxicol, 2011 (2011), p. 431287

64 M.R. Karagas, A. Gossai, B. Pierce, H. AhsanDrinking water arsenic contamination, skin lesions, and malignancies: a systematic review of the global evidence Curr Environ Health Rep, 2 (1) (2015), pp. 52-68

65 D. Han, J. Liu, C. Chen, et al.Anti-tumour immunity controlled through mRNA m 6 A methylation and YTHDF1 in dendritic cells Nature, 566 (7743) (2019), pp. 270-274

66 H. Shi, X. Zhang, Y.L. Weng, et al.m 6 A facilitates hippocampus-dependent learning and memory through YTHDF1 Nature, 563 (7730) (2018), pp. 249-253

67 X. Zong, X. Xiao, B. Shen, et al.The N6-methyladenosine RNA-binding protein YTHDF1 modulates the translation of TRAF6 to mediate the intestinal immune response Nucleic Acids Res, 49 (10) (2021), pp. 5537-5552

68 Y. Shi, S. Fan, M. Wu, et al.YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression Nat Commun, 10 (1) (2019), p. 4892

69 T. Liu, Q. Wei, J. Jin, et al.The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation Nucleic Acids Res, 48 (7) (2020), pp. 3816-3831

70 J. Pi, W. Wang, M. Ji, et al.YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7 Cancer Res, 81 (10) (2021), pp. 2651-2665

71 J. Ye, Z. Wang, X. Chen, et al.YTHDF1-enhanced iron metabolism depends on TFRC m 6 A methylation Theranostics, 10 (26) (2020), pp. 12072-12089

72 E. Linos, S.M. Swetter, M.G. Cockburn, G.A. Colditz, C.A. ClarkeIncreasing burden of melanoma in the United States J Invest Dermatol, 129 (7) (2009), pp. 1666-1674

73 E. Erdei, S.M. TorresA new understanding in the epidemiology of melanoma Expert Rev Anticancer Ther, 10 (11) (2010), pp. 1811-1823

74 D. Schadendorf, A.C.J. van Akkooi, C. Berking, et al. Melanoma. Lancet., 392 (10151) (2018), pp. 971-984

75 N. Li, Y. Kang, L. Wang, et al.ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment Proc Natl Acad Sci USA, 117 (33) (2020), pp. 20159-20170

76 T. Li, M. Gu, A. Deng, C. QianIncreased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis Cancer Cell Int, 20 (2020), p. 239

77 Y. Liao, P. Han, Y. Zhang, B. NiPhysio-pathological effects of m6A modification and its potential contribution to melanoma Clin Transl Oncol, 23 (11) (2021), pp. 2269-2279

78 U. Dahal, K. Le, M. GuptaRNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2 Melanoma Res, 29 (4) (2019), pp. 382-389

79 Z.Y. Feng, T. Wang, X. Su, S. GuoIdentification of the m 6 A RNA methylation regulators WTAP as a novel prognostic biomarker and genomic alterations in cutaneous melanoma Front Mol Biosci, 8 (2021), p. 665222

80 E. Kalo, C. Güvenç, V. Marasigan, D. Lambrechts, J. van den Oord, M. GarmynA variant in FTO gene shows association with histological ulceration in cutaneous melanoma J Cutan Pathol, 47 (1) (2020), pp. 98-101

81 M.M. Iles, M.H. Law, S.N. Stacey, et al.A variant in FTO shows association with melanoma risk not due to BMI Nat Genet, 45 (4) (2013), pp. 428-432 432e1

82 E. Tuncer, R.R. Calçada, D. Zingg, et al.SMAD signaling promotes melanoma metastasis independently of phenotype switching J Clin Invest, 129 (7) (2019), pp. 2702-2716

83 J.M. Ubellacker, A. Tasdogan, V. Ramesh, et al.Lymph protects metastasizing melanoma cells from ferroptosis Nature, 585 (7823) (2020), pp. 113-118

84 K.L. Marie, A. Sassano, H.H. Yang, et al.Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis Nat Commun, 11 (1) (2020), p. 333

85 R. Gowda, B.M. Robertson, S. Iyer, J. Barry, S.S. Dinavahi, G.P. RobertsonThe role of exosomes in metastasis and progression of melanoma Cancer Treat Rev, 85 (2020), p. 101975

86 H. Wu, H. Xu, D. Jia, T. Li, L. XiaMETTL3-induced UCK2 m 6 A hypermethylation promotes melanoma cancer cell metastasis via the WNT/β-catenin pathway Ann Transl Med, 9 (14) (2021), p. 1155

87 S. Huang, S. Lyu, Z. Gao, et al.m6A-related lncRNAs are potential biomarkers for the prognosis of metastatic skin cutaneous melanoma Front Mol Biosci, 8 (2021), p. 687760

88 P.B. Chapman, A. Hauschild, C. Robert, et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med, 364 (26) (2011), pp. 2507-2516

89 K.T. Flaherty, C. Robert, P. Hersey, et al.Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med, 367 (2) (2012), pp. 107-114

90 P. Queirolo, V. Picasso, F. SpagnoloCombined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma Cancer Treat Rev, 41 (6) (2015), pp. 519-526

91 H. Rizos, A.M. Menzies, G.M. Pupo, et al.BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact Clin Cancer Res, 20 (7) (2014), pp. 1965-1977

92 S.Y. Lim, A.M. Menzies, H. RizosMechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma Cancer, 123 (S11) (2017), pp. 2118-2129

93 M.H. Kim, C.G. Kim, S.K. Kim, et al.YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma Cancer Immunol Res, 6 (3) (2018), pp. 255-266

94 S. Shen, S. Faouzi, A. Bastide, et al.An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells Nat Commun, 10 (1) (2019), p. 5713

95 D.M. PardollThe blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer, 12 (4) (2012), pp. 252-264

96 C. Robert, G.V. Long, B. Brady, et al.Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med, 372 (4) (2015), pp. 320-330

97 J.D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med, 377 (14) (2017), pp. 1345-1356

98 M.K. Callahan, H. Kluger, M.A. Postow, et al.Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study J Clin Oncol, 36 (4) (2018), pp. 391-398

99 C. Imbert, A. Montfort, M. Fraisse, et al.Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 Nat Commun, 11 (1) (2020), p. 437

100 I. Pires da Silva, T. Ahmed, I.L.M. Reijers, et al.Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study Lancet Oncol, 22 (6) (2021), pp. 836-847

101 L. Wang, H. Hui, K. Agrawal, et al.m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy EMBO J, 39 (20) (2020), p. e104514

102 J. Meng, X. Huang, Y. Qiu, M. Yu, J. Lu, J. YaoCharacterization of m6A-related genes landscape in skin cutaneous melanoma to aid immunotherapy and assess prognosis Int J Gen Med, 14 (2021), pp. 5345-5361

103 Y. Niu, Z. Lin, A. Wan, et al.RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3 Mol Cancer, 18 (1) (2019), p. 46

104 K. Kumari, P. Groza, F. AguiloRegulatory roles of RNA modifications in breast cancer NAR Cancer, 3 (3) (2021), p. zcab036

105 Y. Xiao, K.N. Thakkar, H. Zhao, et al.The m 6 A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor Proc Natl Acad Sci USA, 117 (35) (2020), pp. 21441-21449

106 B.A. van Gorkom, H. Timmer-Bosscha, S. de Jong, D.M. van der Kolk, J.H. Kleibeuker, E.G. de VriesCytotoxicity of Rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1 Br J Cancer, 86 (9) (2002), pp. 1494-1500

107 L. Yang, J. Li, L. Xu, et al.Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway Cancer Manag Res, 11 (2019), pp. 1167-1176

108 Y. Huang, J. Yan, Q. Li, et al.Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 Nucleic Acids Res, 43 (1) (2015), pp. 373-384

109 D. Kovala-Demertzi, V. Dokorou, A. Primikiri, et al.Organotin meclofenamic complexes: synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid - novel anti-tuberculosis agents J Inorg Biochem, 103 (5) (2009), pp. 738-744

110 D. Kovala-Demertzi, M. Staninska, I. Garcia-Santos, A. Castineiras, M.A. DemertzisSynthesis, crystal structures and spectroscopy of meclofenamic acid and its metal complexes with manganese(II), copper(II), zinc(II) and cadmium(II). Antiproliferative and superoxide dismutase activity J Inorg Biochem, 105 (9) (2011), pp. 1187-1195

111 S. Huff, S.K. Tiwari, G.M. Gonzalez, Y. Wang, T.M. Ranam 6 A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells ACS Chem Biol, 16 (2) (2021), pp. 324-333

112 Y. Huang, R. Su, Y. Sheng, et al.Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia Cancer Cell, 35 (4) (2019), pp. 677-691 e10

113 M. Wang, J. Liu, Y. Zhao, et al.Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer Mol Cancer, 19 (1) (2020), p. 130

114 L. Cheng, X. Zhang, Y.Z. Huang, et al.Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway Oncogenesis, 10 (1) (2021), p. 7

115 J. Liu, M.A. Eckert, B.T. Harada, et al.m 6 A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer Nat Cell Biol, 20 (9) (2018), pp. 1074-1083

116 I. Barbieri, K. Tzelepis, L. Pandolfini, et al.Promoter-bound METTL3 maintains myeloid leukaemia by m 6 A-dependent translation control Nature, 552 (7683) (2017), pp. 126-131

117 E. Yankova, W. Blackaby, M. Albertella, et al.Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia Nature, 593 (7860) (2021), pp. 597-601

118 S. Selberg, D. Blokhina, M. Aatonen, et al.Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site Cell Rep, 26 (13) (2019), pp. 3762-3771 e5

119 H. Easwaran, H.C. Tsai, S.B. BaylinCancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance Mol Cell, 54 (5) (2014), pp. 716-727

120 O. Shriwas, P. Mohapatra, S. Mohanty, R. DashThe impact of m6A RNA modification in therapy resistance of cancer: implication in chemotherapy, radiotherapy, and immunotherapy Front Oncol, 10 (2021), p. 612337

121 X. Pan, X. Hong, S. Li, P. Meng, F. XiaoMETTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner Exp Mol Med, 53 (1) (2021), pp. 91-102

122 Z. Lin, Y. Niu, A. Wan, et al.RNA m 6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy EMBO J, 39 (12) (2020), p. e103181

123 T. Bu, C. Wang, H. Jin, et al.Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and Rhein J Cell Physiol, 235 (4) (2020), pp. 3309-3319

124 S. Yang, J. Wei, Y. Cui, et al.m 6 A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade Nat Commum, 10 (1) (2019), p. 2782